ARTICLE | Clinical News
AZD5363: Phase I started
April 18, 2011 7:00 AM UTC
AstraZeneca began an open-label, European Phase I trial to evaluate ascending-doses of oral AZD5363 in about 84 patients. AstraZeneca has worldwide rights to the compound from Astex (see BioCentury Au...